Sep 20th 2012 - Edison Investment Research today published a report on TiGenix entitled "Achieving The Targets". In summary, the report says:
Total 2012 revenues could be about €3.9m, with the operating loss falling by 15% to €19.2m. The Dutch healthcare system now fully reimburses ChondroCelect, enabling TiGenix to invest in marketing in Holland, where four leading hospitals now use the product. The interims showed a one-off gain of €0.7m for the ‘risk-share’ element of 2011 Dutch sales. A big EU country (Spain or France) needs to give reimbursement soon to hit 2013 sales targets. The Cx601 perianal fistula study started in July. The Cx621 intralymphatic safety study showed that direct injection is safe.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »